Treatment of optic neuropathies state of the art;Therapie von sehnerverkrankungen der aktuelle stand

Klinische Monatsblatter fur Augenheilkunde

Volumn 226, Issue 11, 2009, Pages 875-880

  Lagreze W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Optic atrophy; Optic nerve; Steroids; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ATACICEPT; BISPHOSPHONIC ACID DERIVATIVE; CD20 ANTIBODY; CORTICOSTEROID; CURCUMIN; FINGOLIMOD; HYBRID PROTEIN; HYDROXOCOBALAMIN; INTERLEUKIN 4; METHYLPREDNISOLONE; NATALIZUMAB; OMEPRAZOLE; RANIBIZUMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UBIQUINONE; ANTIINFLAMMATORY AGENT;

APOPTOSIS; ARTERIOVENOUS SHUNT; CD4 CD8 RATIO; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; EXOPHTHALMOS; EYE DISEASE; EYE SURGERY; GLAUCOMA; HUMAN; IMMUNOMODULATION; INFLAMMATION; ISCHEMIA; ISCHEMIC OPTIC NEUROPATHY; MULTIPLE SCLEROSIS; NEOPLASM; NERVE FIBER DEGENERATION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE ATROPHY; OPTIC NERVE DISEASE; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA DEGENERATION; REVIEW; SENSITIVITY AND SPECIFICITY; THROMBOSIS PREVENTION; TRAUMATIC OPTIC NEUROPATHY; TREATMENT INDICATION; VISUAL DISORDER; DISEASE COURSE; OPTIC DISK ANOMALY; OPTIC NERVE INJURY; OPTIC NERVE TUMOR; PAPILLEDEMA; PROGNOSIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; DISEASE PROGRESSION; HUMANS; OPTIC ATROPHY; OPTIC DISK DRUSEN; OPTIC NERVE DISEASES; OPTIC NERVE INJURIES; OPTIC NERVE NEOPLASMS; OPTIC NEURITIS; OPTIC NEUROPATHY, ISCHEMIC; PAPILLEDEMA; PROGNOSIS;

EID: 77449114154     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109728     Document Type: Review

References (58)

1. Trautner C, Haastert B, Richter B et al. Incidence of blindness in southern Germany due to glaucoma and degenerative conditions. Invest Ophthalmol Vis Sci 2003 44 1031-1034
2. Heijl A, Leske M C., Bengtsson B et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002 120 1268-1279
3. Beck R W., Gal R L., Bhatti M T. et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 2004 137 77-83
4. Trapp B D., Peterson J, Ransohoff R M. et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998 338 278-285
5. Steel D H., Waldock A. Measurement of the retinal nerve fibre layer with scanning laser polarimetry in patients with previous demyelinating optic neuritis. J Neurol Neurosurg Psychiatry 1998 64 505-509
6. Trip S A., Schlottmann P G., Jones S J. et al. Retinal Nerve Fiber Layer Axonal Loss and Visual Dysfunction in Optic Neuritis. Ann Neurol 2005 58 383-391
7. Frohman E, Costello F, Zivadinov R et al. Optical coherence tomography in multiple sclerosis. Lancet Neurol 2006 5 853-863
8. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006 355 1124-1140
9. McDonald W I., Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 50 121-127
10. Polman C H., Reingold S C., Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005 58 840-846
11. Lagréze W A. Steroids for optic nerve diseases? Ophthalmologe 2007 104 517-520
12. Beck R W., Cleary P A., Anderson M M. et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992 326 581-588
13. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 1997 49 1404-1413
14. Gould E S., Bird A C., Leaver P K. et al. Treatmenf of optic neuritis by retrobulbar injection of triamcinolone. Br Med J 1977 1 1495-1497
15. Trauzettel-Klosinski S Jr, Diener H C., Dietz K et al. The effect of oral prednisolone on visual evoked potential latencies in acute optic neuritis monitored in a prospective, randomized, controlled study. Doc Ophthalmol 1995 91 165-179
16. Sellebjerg F, Nielsen H S., Frederiksen J L. et al. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999 52 1479-1484
17. Wakakura M, Mashimo K, Oono S et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 1999 43 133-138
18. Vedula S, Brodney-Folse S, Gal R et al. Corticosteroids for treating optic neuritis. Cochrane database of systematic reviews (Online) 2007 CD001430
19. Hickman S J., Kapoor R, Jones S J. et al. Corticosteroids do not prevent optic nerve atrophy following optic neuritis. JNeurol Neurosurg Psychiatry 2003 74 1139-1141
20. Diem R, Hobom M, Maier K et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 2003 23 6993-7000
21. Lennon V A., Wingerchuk D M., Kryzer T J. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004 364 2106-2112
22. Kidd D, Burton B, Plant G T. et al. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003 126 276-284
23. Jacob A, Weinshenker B G., Violich I et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008 65 1443-1448
24. Ruprecht K, Klinker E, Dintelmann T et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004 63 1081-1083
25. Bley T A., Uhl M, Carew J et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. Am J Neuroradiol 2007 28 1722-1727
26. Hayreh S S., Zimmerman B, Kardon R H. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta ophthalmologica Scandinavica 2002 80 355-367
27. Buono L M., Foroozan R, Sergott R C. et al. Nonarteritic anterior ischemic optic neuropathy. Current opinion in ophthalmology 2002 13 357-361
28. Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Arch Ophthalmol 2000 118 793-798
29. Dickersin K, Manheimer E, Li T. Surgery for nonarteritic anterior ischemic optic neuropathy. Cochrane database of systematic reviews (Online) 2006 CD001538
30. Fraser S, Siriwardena D. Interventions for acute non-arteritic central retinal artery occlusion. Cochrane database of systematic reviews (Online) 2002 CD001989
31. Hayreh S S., Zimmerman M B. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 2008 246 1029-1046
32. Newman N J., Scherer R, Langenberg P et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 2002 134 317-328
33. Beck R W., Hayreh S S., Podhajsky P A. et al. Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997 123 212-217
34. Salomon O, Huna-Baron R, Steinberg D M. et al. Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye 1999 13 (Pt 3a) 357-359
35. Kupersmith M J., Frohman L, Sanderson M et al. Aspirin reduces the incidence of second eye NAION: a retrospective study. J Neuroophthalmol 1997 17 250-253
36. Mathews M K., Sergott R C., Savino P J. Pseudotumor cerebri. Current opinion in ophthalmology 2003 14 364-370
37. Ahlskog J E., ONeill B P. Pseudotumor cerebri. Ann Intern Med 1982 97 249-256
38. Steinsapir K D. Treatment of traumatic optic neuropathy with high-dose corticosteroid. J Neuroophthalmol 2006 26 65-67
39. Bracken M B., Shepard M J., Collins W F. et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990 322 1405-1411
40. Bracken M B., Shepard M J., Holford T R. et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. Jama 1997 277 1597-1604
41. Roberts I, Yates D, Sandercock P et al. Effect of intravenous corticosteroids on death within 14 days in 10 008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004 364 1321-1328
42. Yip C C., Chng N W., Au Kong K G. et al. Low-dose intravenous methylprednisolone or conservative treatment in the management of traumatic optic neuropathy. Eur J Ophthalmol 2002 12 309-314
43. Levin L A., Beck R W., Joseph M P. et al. The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Ophthalmology 1999 106 1268-1277
44. Ohlsson M, Mattsson P, Svensson M. A temporal study of axonal degeneration and glial scar formation following a standardized crush injury of the optic nerve in the adult rat. Restor Neurol Neurosci 2004 22 1-10
45. Ohlsson M, Westerlund U, Langmoen I A. et al. Methylprednisolone treatment does not influence axonal regeneration or degeneration following optic nerve injury in the adult rat. J Neuroophthalmol 2004 24 11-18
46. Sheng Y, Zhu Y, Wu L. Effect of high dosage of methylprednisolone on rat retinal ganglion cell apoptosis after optic nerve crush. Yan Ke Xue Bao 2004 20 181-186
47. Steinsapir K D., Goldberg R A., Sinha S et al. Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats. Restor Neurol Neurosci 2000 17 157-163
48. Schargus M, Gramer E. Optic disc drusen. Ophthalmologe 2008 105 693-710
49. Auw-Haedrich C, Staubach F, Witschel H. Optic disk drusen. Surv Ophthalmol 2002 47 515-532
50. Puomila A, Hamalainen P, Kivioja S et al. Epidemiology and penetrance of Leber hereditary optic neuropathy in Finland. Eur J Hum Genet 2007 15 1079-1089
51. Spruijt L, Kolbach D N., Coo R F. et al. Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. Am J Ophthalmol 2006 141 676-682
52. Barnils N de, Mesa E, Munoz S et al. Response to idebenone and multivitamin therapy in Lebers hereditary optic neuropathy. Archivos de la Sociedad Espanola de Oftalmologia 2007 82 377-380
53. rd J F., Lessell S. Optic neuropathy after burns. Arch Ophthalmol 2000 118 1696-1698
54. Klewin K M., Appen R E., Kaufman P L. Amaurosis and blood loss. Am J Ophthalmol 1978 86 669-672
55. Sadun A A., Martone J F., Muci-Mendoza R et al. Epidemic optic neuropathy in Cuba. Eye findings. Arch Ophthalmol 1994 112 691-699
56. Lee A G. Neuroophthalmological management of optic pathway gliomas. Neurosurg Focus 2007 23 E1
57. Pitz S, Becker G, Schiefer U et al. Stereotactic fractionated irradiation of optic nerve sheath meningioma: a new treatment alternative. Br J Ophthalmol 2002 86 1265-1268
58. Wilhelm H. Primary optic nerve tumours. Curr Opinion Neurol 2009 22 11-18